Pen-type injector having an electronic control unit
Abstract
An injection device having a drive mechanism to expel selectively a dose of medicament from a medicament cartridge through a needle unit is disclosed. The injection device further comprises an electronic control unit to control the drive mechanism, and a dispense button to generate a dispense button signal to the electronic control unit indicative of the dose to be expelled in which an arm button causes a first arm button signal to be sent to the electronic control unit to permit the dose to be expelled.

Term
Term ended
Expired 21 December 2021, 4.8 years ago.
- Priority
- Filed
- Granted
- Expired
- Today
5 claims: 5 independent, 0 dependent
- 1An injection device having a drive mechanism (42) to expel selectively a dose of medicament from a medicament cartridge (40) through a needle unit (22), an electronic control unit to control the drive mechanism (42), dose buttons (12, 14) to select a desired dosage, and a dispense button (18) to generate a dispense button signal to the electronic control unit indicative of the dose to be expelled and an arm button (16), in which the arm button (16) causes a first arm button signal to be sent to the electronic control unit to permit the dose to be expelled, wherein the arm button (16) is linked to a cover detection switch (28) such that the arm button will only function to arm an injector (2) when a cover (6) is not present. Dispositif d'injection ayant un mécanisme d'entraînement (42) pour expulser de manière sélective une dose de médicament d'une cartouche de médicament (40) à travers une unité d'aiguille (22), une unité de commande électronique pour commander le mécanisme d'entraînement (42) des boutons de dosage (12, 14) pour sélectioner une dose voulue, et un bouton de distribution (18) pour envoyer un signal du bouton de distribution à l'unité de commande électronique, indiquant la dose à expulser et un bouton d'enclenchement (16), le bouton d'enclenchement (16) provoquant l'envoi d'un premier signal du bouton d'enclenchement à l'unité de commande électronique pour permettre d'expulser la dose, le bouton d'enclenchement (16) étant relié à un commutateur de détection de couvercle (28) de telle sorte que le bouton d'enclenchement ne fonctionne pour armer un injecteur (2) que lorsqu'un couvercle (6) est enlevé. Injektionsvorrichtung, welche einen Antriebsmechanismus (42) aufweist, um selektiv eine Dosis eines Medikaments von einer Medikamentenkartusche (40) durch eine Nadeleinheit (22) auszustoßen, eine elektronische Kontrolleinheit, um den Antriebsmechanismus (42) zu steuern, Dosisknöpfe (12, 14), um eine gewünschte Dosis auszuwählen, und einen Verabreichungsknopf (18), um ein Verabreichungsknopfsignal für die elektronische Steuereinheit zu erzeugen, welches die auszustoßende Dosis angibt, und einen Aktivierungsknopf (16), wobei der Aktivierungsknopf (16) verursacht, dass ein erstes Aktivierungsknopfsignal an die elektronische Steuereinheit gesendet wird, um zu ermöglichen, dass die Dosis ausgestoßen wird, wobei der Aktivierungsknopf (16) mit einem Abdeckungserkennungsschalter (28) verbunden ist, so dass der Aktivierungsknopf nur dann funktioniert, um einen Injektor (2) zu aktivieren, wenn keine Abdeckung (6) vorhanden ist.
- 2An injection device according to claim 1 characterised in that when the dispense button signal is not generated within a predetermined period of the arm signal, the electronic control unit will not actuate the drive mechanism (42) in response to the dispense button signal. Dispositif d'injection selon la revendication 1, caractérisé en ce que lorsque le signal du bouton de distribution n'est pas produit pendant une période prédéterminée du signal d'enclenchement, l'unité de commande électronique n'actionnera pas le mécanisme d'entraînement (42) en réponse au signal du bouton de distribution. Injektionsvorrichtung gemäß Anspruch 1, dadurch gekennzeichnet, dass, wenn das Verabreichungsknopfsignal nicht innerhalb einer vorher bestimmten Zeitspanne zum Aktivierungssignal erzeugt wird, die elektronische Steuereinheit den Antriebsmechanismus (42) nicht in Reaktion auf das Verabreichungsknopfsignal betätigt.
- 3An injection device according to claim 1 or claim 2 characterised in that the arm button must generate the first arm button signal for a predetermined period of time before the electronic control unit will respond to the dispense button signal. Dispositif d'injection selon la revendication 1 ou la revendication 2, caractérisé en ce que le bouton d'enclenchement doit produire le premier signal du bouton d'enclenchement pendant une période de temps prédéterminée avant que l'unité de commande électronique ne réponde au signal du bouton de distribution. Injektionsvorrichtung gemäß Anspruch 1 oder Anspruch 2, dadurch gekennzeichnet, dass der Aktivierungsknopf das erste Aktivierungsknopfsignal eine vorher bestimmte Zeitspanne lang erzeugen muss, bevor die elektronische Steuereinheit auf das Verabreichungsknopfsignal reagiert.
- 4An injection device according to any of claims 1 to 3 characterised in that the injection device is additionally provided with a display panel (10), the display panel (10) providing an indication that the dose is permitted to be expelled. Dispositif d'injection selon l'une quelconque des revendications 1 à 3, caractérisé en ce que le dispositif d'injection est en outre pourvu d'un panneau d'affichage (10), le panneau d'affichage (10) indiquant que la dose peut être expulsée. Injektionsvorrichtung gemäß einem der Ansprüche 1 bis 3, dadurch gekennzeichnet, dass die Injektionsvorrichtung zusätzlich mit einem Anzeigefeld (10) versehen ist, wobei das Anzeigefeld (10) eine Angabe bereitstellt, dass es der Dosis ermöglicht wird, ausgestoßen zu werden.
- 5An injection device according to any of claims 1 to 4 characterised in that when the arm button generates a subsequent arm button signal within a predetermined period of the first arm button signal, the electronic control unit will not actuate the drive mechanism (42) in response to the dispense button signal. Dispositif d'injection selon l'une quelconque des revendications 1 à 4, caractérisé en ce que, lorsque le bouton d'enclenchement produit un signal du bouton d'enclenchement subséquent durant une période prédéterminée du premier signal du bouton d'enclenchement, l'unité de commande électronique n'actionnera pas le mécanisme d'entraînement (42) en réponse au signal du bouton de distribution. Injektionsvorrichtung gemäß einem der Ansprüche 1 bis 4, dadurch gekennzeichnet, dass, wenn der Aktivierungsknopf ein nachfolgendes Aktivierungsknopfsignal innerhalb einer vorher bestimmten Zeitspanne zum ersten Aktivierungsknopfsignal erzeugt, die elektronische Steuereinheit den Antriebsmechanismus (42) in Reaktion auf das Verabreichungsknopfsignal nicht betätigt.
Independent claims5
39 paragraphs, as filed
The present invention relates to improvements in an injection device, and in particular to improvements in a portable injection device for dispensing controlled quantities of a medicament.
Typically such injection devices are used by those suffering from diabetes to administer a dose of insulin or insulin-type medicine to themselves. It will be understood that such injection devices are suitable for the injection of other medicines.
At one time, such doses were administered by use of a disposable syringe; the syringe first being filled from a separate phial or other container and then used to inject the dose. However, there were a number of difficulties in such an arrangement. In particular, such an arrangement was not suitable for the infirm. For others, the social stigma associated with such syringes made their public use problematic.
To overcome these difficulties a number of so-called pen-type injectors have been developed. These devices are small, being capable of being carried in a jacket pocket or the like and allow a number of doses to be obtained from a cartridge or ampoule contained within the injector. The present invention has particular application to such pen-type injectors.
While such pen-type injectors are a considerable improvement upon disposable hypodermic syringes, problems nevertheless remain. It is an advantage of the present invention that it eliminates, or at least substantially reduces such problems. The present invention also provides for improved ease of use and improved interaction with a user.
The invention will now be described, by way of example only, with reference to the accompanying drawings; in which:- <ul id="ul0001" list-style="none" compact="compact"><li><figref idref="f0001">Figure 1</figref> shows a plan view of a pen-type injector in accordance with the present invention;</li><li><figref idref="f0001">Figure 2</figref> shows a similar view to <figref idref="f0001">Figure 1</figref> with an end cap of the injector omitted;</li><li><figref idref="f0002">Figure 3</figref> shows a cross-sectional view of the injector of <figref idref="f0001">Figures 1 and 2</figref>; and</li><li><figref idref="f0003">Figure 3A</figref> shows a view similar to that of <figref idref="f0002">Figure 3</figref> with a filled cartridge in the injector.</li></ul>
Referring first to <figref idref="f0001 f0002 f0003">Figures 1 to 3</figref>, there can be seen a pen-type injector 2 in accordance with the present invention. The injector 2 comprises a main housing 4 to which is releasably secured an end cap or cover 6.
At a first end of the main housing 4 there is provided a control panel region 8. This region includes a display panel 10, typically a LCD display, and a first dose button 12 and a second dose button 14, the first and second dose buttons being operated to increase or decrease a dose of medicament to be delivered. The control panel region 10 in the illustrated embodiment also includes an arm button 16.
At the first end of the main housing there is also provided a dispense button 18. Preferably, when not depressed, the dispense button 18 is flush with the main housing 4.
Along a longitudinal axis of the injector 2, to each side of the control panel region 10 are provided a number of grooves or recesses 20. These aid in the gripping of the injector 2 by a user.
At a second end of the main housing 4 a needle unit 22 is releasably secured to the main housing. The second end of the main housing 4 is also provided with a shaped portion 24.
In use a cartridge 40 or ampoule of medicament is stored in the housing 4 behind the shaped portion 24. For preference, the shaped portion is transparent to permit the cartridge 40 to be seen by a user.
A primer button 26 is also provided on the second end of the housing 4. It will be understood that when the end cap 6 is in place over the second end of the housing, it will not be possible inadvertently to depress the primer button 26 or to be pricked by the needle unit 22. A cover detection switch 28 may also be included at the second end of the main housing 4 to detect whether the end cap or cover 6 is in place or not.
In <figref idref="f0002">Figure 3</figref>, there can be seen a priming contact 30, an arm contact 32, a first dose contact 34 and a second dose contact 36 corresponding to the respective buttons. A dispense contact 19 corresponding to the dispense button 18 is also shown.
With reference to <figref idref="f0002">Figure 3</figref> it may be seen that there is provided a suitable location for a power source 38 such as a battery or batteries. There is also a suitable region in which a cartridge 40 or ampoule of medicament is to be located. This region may be accessed by way of the removable shaped portion 24 of the main housing 4 to allow for replacement of the cartridge 40 or ampoule as required by the user.
In a third region of the main housing 4 there is provided a drive mechanism 42 which operates from the power source 38 and acts upon the cartridge 40 or ampoule of medicament.
The cartridge 40 or ampoule comprises a container 44 or sleeve closed at one end by a cover 46 at a head end thereof, and sealed at the other by a movable bung 48 or stopper. When in position, the needle unit 22 pierces the cover 46 and movement of the bung 48 towards the cover 46 will cause the medicament contained within the cartridge 40 or ampoule to be expelled. The cartridge may be a 3ml cartridge in accordance with ISO/FDIS 11608 Part 3, or any other suitable cartridge to suit the injector.
Movement of the bung 48 or stopper is caused by movement of a piston or plunger 50 forming a part of the drive mechanism 42. The piston or plunger 50 is movable between a first fully withdrawn position (not shown) which allows for the replacement of the cartridge 40 or ampoule and a second fully extended portion in which as much medicament as possible has been expelled from the cartridge 40 or ampoule. An end stop switch 52 may be provided in the main housing 4 to detect when the piston 50 is in the fully withdrawn position. Tripping of the switch end stop 52 may release a catch or other fastening device to allow access to the main housing 4 for replacement of the cartridge 40.
The drive mechanism 42 is operated by a motor 54 under the control of an electronic control unit (not shown). The motor 54 should be reversible in order to allow the piston 50 to be moved between the first and second positions. In <figref idref="f0002">Figure 3</figref>, the motor 54 can be seen to drive the piston 50 by way of a gear train 42, such that rotation of a third rotor 58 causes the piston 50 to be moved in relation to the third rotor 58.
Preferably, the user can feel the vibration of the motor 54 and the associated drive mechanism 42 and/or hear them in operation. In this way an added degree of confidence in the fact of the operation of the injector 2 is provided to the user.
The functionality of a pen-type injector in accordance with the present invention will now be described, in particular with reference to <figref idref="f0001">Figures 1, 2</figref> and <figref idref="f0002">3</figref>.
The injector 2 is provided with an electronic control unit. The electronic control unit is coupled both to the drive mechanism and a user interface. The user interface includes the display panel 10 as well as the user operable buttons (and associated contacts). The electronic control unit is microprocessor based. Either volatile or non-volatile memory may be used for storage of 'dose history' and patient specific information.
The electronic control unit is preferably powered from the injector power source 38.
The injector 2 preferably also includes a port for communication between the electronic control unit and an external apparatus such as a personal computer.
The injector 2 also has a priming detection facility, (such as a tilt switch or accelerometer) to identify when the injector 2 is inverted. On detection of an inverted position (needle up) the injector 2 will automatically change state to be ready for priming. Priming may be initiated by depression of the primer button 26 to cause a fixed small dispense action. The electronic control unit may cause a speaker to sound when the primer button 26 is depressed.
The primer button 26 is inactive at all other times. When the primer button 26 is active, all other buttons in the control panel region are inactive, that is those buttons which are to be used to set or dispense a dose.
The electronic control unit may cause a speaker to sound when the arm button 16 is depressed for a sufficient period of time to provide audible feedback for the user.
The function of the arm button 16 is to make the dispense button 18 active. The arm button is preferably held down for a predetermined period of time before the injector 2 becomes armed. The armed status may additionally be shown on the display panel 10. The functionality of the arm button is linked to the cover detection switch 28 such that the arm button 16 will only function to arm the injector 2 when the cover 6 is not present.
Additionally, in a preferred embodiment, a clock within the electronic control unit will detect whether the dispense button 18 has been pressed within a specified time interval following arming of the injector 2. If the dispense button 18 has not been depressed within the specified time interval the electronic control unit will disarm the injector 2. Alternatively, if the arm button is depressed a second time within a predetermined time period by the user, the injector will be disabled.
In an alternative embodiment, the dose button18 may function as both a prime button and the dose button. When the priming detector is actuated, by the injector 2 being oriented needle up, the dose button 18 would change function to that of the prime button of the previous embodiment.
The buttons of the injector 2 are preferably tactile in nature to provide sensory feedback to the user.
The display panel 10 is typically an LCD display and will provide alphanumeric and graphical information relating to the operation of the device. The display panel 10 preferably indicates the selected dose quantity, the previous dose quantity and the time elapsed since the previous dose was administered. Typically, the time elapsed since the previous dose is limited to a time period within the preceding 48 hours, though other time periods are possible.
Additional information which may be displayed includes: <ul id="ul0002" list-style="dash" compact="compact"><li>that the injector is armed and ready to dispense (graphical)</li><li>that the injector is dispensing (graphical)</li><li>that the injector has dispensed the selected dose and that a user should wait before removing the needle from their body</li><li>that this waiting period has elapsed</li><li>the dose history, typically for the last 48 hours, in terms of the dosage taken and the elapsed time between doses</li><li>the quantity of medicament remaining in the cartridge, preferably in terms of dosage units of the medicament.</li><li>that the device is in the priming position (either in addition to or instead of the acoustic indication noted above)</li><li>the speaker volume setting, for example high, low or muted.</li><li>that the injector is nearing the end of its life (for example a battery power level indication - graphical or countdown in terms of the number of days or complete operating cycles to a predetermined expiry of the product life - alphanumeric).</li><li>that the needle is probably blocked</li><li>that replacement of the cartridge 40 is in progress</li><li>that the dose selected is the maximum available in the cartridge 40</li><li>that the maximum dose available is less than the dose expected.</li></ul>
The display panel 10 may offer a user a choice of language options as appropriate for the market and/or user. The text displayed may include that noted above and/or further information. The language option may be pre-programmed or selectable by a user. The user may preferably select the language option by means of a menu provided on the display panel 10.
The currently selected dose value, the previously used dose value and the time (in hours) since the previous dose was dispensed, may all be shown clearly at the same time, in large, easy-to-read characters on the display. Preferably, the display is also provided with a backlight.
The display 10 preferably provides a graphical indication that the selected dose is being dispensed. This may be achieved, for example, as either an animated graphic or a countdown (or a combination of both).
The control buttons have a number of functions. The dose buttons 12,14 allow a user to select a desired dosage. The dose arm button 16 allows a user to confirm selection of a desired dosage. The first dose button can increment the dosage level and the second dose button can decrement the dosage level. The dose dialling buttons 12,14 may be pressed down (and held for a short time, 1-2 seconds) to re-set a dose value to zero. The user can then dial up (or down) in single (or half) increments.
The dose dialling buttons 12,14 are intended to be pressed once for a single (or half) increment in the selected dose value. In an alternative embodiment, pressing and holding one of the buttons will cause the dose value to start to scroll (up or down) in order to change the dose size more rapidly.
The dispense button 18 allows a user to initiate dispensing of the dosage. The primer button 26 dispenses a unit of dosage from the cartridge 40. Thus, if any air is trapped in the injector 2 this can be expelled by use of the primer button 26. A door release catch is provided to allow access to the cartridge 40.
3 sheets
Sheet 1 Sheet 2 Sheet 3
Every citation, both ways
| Document | Relation | Office | Cited during |
|---|---|---|---|
| WO0069488A2 | Cites | World Intellectual Property Organization (WIPO) | Opposition |
| EP1223998A2 | Cites | European Patent Office (EPO) | Opposition |
| WO9733638A1 | Cites | World Intellectual Property Organization (WIPO) | Opposition |
| CH665955A | Cites | Switzerland | – |
| EP1223998A2 | Cites | European Patent Office (EPO) | – |
| US5728074A | Cites | United States of America | – |
| WO0048112A | Cites | World Intellectual Property Organization (WIPO) | – |
| WO0069488A2 | Cites | World Intellectual Property Organization (WIPO) | – |
| WO9302720A | Cites | World Intellectual Property Organization (WIPO) | – |
| WO9733638A | Cites | World Intellectual Property Organization (WIPO) | – |
| WO9733638A1 | Cites | World Intellectual Property Organization (WIPO) | – |
350 members in 19 offices
Priority claims9
| Document | Office | Kind | Date |
|---|---|---|---|
| 0031466 | United Kingdom | A | |
| 0031466 | United Kingdom | A | |
| 0031466 | United Kingdom | – | |
| 0105711 | United Kingdom | W | |
| 0105711 | United Kingdom | W | |
| 0031466 | – | – | – |
| GB20000031466 | – | – | – |
| GB2001005711 | – | – | – |
| WO2001GB05711 | – | – | – |
Members350
| Document | Office | Kind | |
|---|---|---|---|
| GB0031466D0 | United Kingdom | D0 | |
| CA2430788A1 | Canada | A1 | |
| CA2430917A1 | Canada | A1 | |
| CA2430920A1 | Canada | A1 | |
| CA2430922A1 | Canada | A1 | |
| CA2430925A1 | Canada | A1 | |
| CA2430928A1 | Canada | A1 | |
| CA2430931A1 | Canada | A1 | |
| CA2430935A1 | Canada | A1 | |
| CA2430938A1 | Canada | A1 | |
| CA2430940A1 | Canada | A1 | |
| CA2431135A1 | Canada | A1 | |
| WO02051471A1 | World Intellectual Property Organization (WIPO) | A1 | |
| WO02051472A1 | World Intellectual Property Organization (WIPO) | A1 | |
| WO02051473A1 | World Intellectual Property Organization (WIPO) | A1 | |
| WO02051474A1 | World Intellectual Property Organization (WIPO) | A1 | |
| WO02051475A1 | World Intellectual Property Organization (WIPO) | A1 | |
| WO02051476A1 | World Intellectual Property Organization (WIPO) | A1 | |
| WO02051477A1 | World Intellectual Property Organization (WIPO) | A1 | |
| WO02051478A1 | World Intellectual Property Organization (WIPO) | A1 | |
| WO02051479A1 | World Intellectual Property Organization (WIPO) | A1 | |
| WO02051480A1 | World Intellectual Property Organization (WIPO) | A1 | |
| WO02051481A1 | World Intellectual Property Organization (WIPO) | A1 | |
| CA2430914A1 | Canada | A1 | |
| CA2430942A1 | Canada | A1 | |
| WO02058766A1 | World Intellectual Property Organization (WIPO) | A1 | |
| WO02058767A1 | World Intellectual Property Organization (WIPO) | A1 | |
| KR20030066724A | Republic of Korea | A | |
| KR20030066725A | Republic of Korea | A | |
| KR20030066726A | Republic of Korea | A | |
| KR20030066727A | Republic of Korea | A | |
| KR20030066728A | Republic of Korea | A | |
| KR20030066729A | Republic of Korea | A | |
| KR20030066738A | Republic of Korea | A | |
| KR20030066739A | Republic of Korea | A | |
| KR20030066740A | Republic of Korea | A | |
| KR20030066741A | Republic of Korea | A | |
| KR20030066742A | Republic of Korea | A | |
| KR20030066743A | Republic of Korea | A | |
| EP1345641A1 | European Patent Office (EPO) | A1 | |
| EP1349587A1 | European Patent Office (EPO) | A1 | |
| EP1349588A1 | European Patent Office (EPO) | A1 | |
| EP1349591A1 | European Patent Office (EPO) | A1 | |
| EP1349592A1 | European Patent Office (EPO) | A1 | |
| EP1349593A1 | European Patent Office (EPO) | A1 | |
| EP1349594A1 | European Patent Office (EPO) | A1 | |
| EP1349595A1 | European Patent Office (EPO) | A1 | |
| EP1349596A1 | European Patent Office (EPO) | A1 | |
| EP1351728A1 | European Patent Office (EPO) | A1 | |
| EP1353712A1 | European Patent Office (EPO) | A1 | |
| EP1353713A1 | European Patent Office (EPO) | A1 | |
| EP1353715A1 | European Patent Office (EPO) | A1 | |
| BR0116273A | Brazil | A | |
| BR0116274A | Brazil | A | |
| BR0116275A | Brazil | A | |
| BR0116276A | Brazil | A | |
| BR0116277A | Brazil | A | |
| BR0116278A | Brazil | A | |
| BR0116279A | Brazil | A | |
| BR0116280A | Brazil | A | |
| IL156238D0 | Israel | D0 | |
| IL156239D0 | Israel | D0 | |
| IL156240D0 | Israel | D0 | |
| IL156241D0 | Israel | D0 | |
| IL156242D0 | Israel | D0 | |
| IL156243D0 | Israel | D0 | |
| IL156244D0 | Israel | D0 | |
| IL156245D0 | Israel | D0 | |
| IL156246D0 | Israel | D0 | |
| IL156247D0 | Israel | D0 | |
| IL156248D0 | Israel | D0 | |
| IL156251D0 | Israel | D0 | |
| IL156270D0 | Israel | D0 | |
| US2004024364A1 | United States of America | A1 | |
| US2004030296A1 | United States of America | A1 | |
| US2004030298A1 | United States of America | A1 | |
| US2004044317A1 | United States of America | A1 | |
| CN1481261A | China | A | |
| CN1481262A | China | A | |
| US2004049156A1 | United States of America | A1 | |
| CN1482926A | China | A | |
| CN1482927A | China | A | |
| CN1482928A | China | A | |
| CN1482929A | China | A | |
| CN1482930A | China | A | |
| CN1482931A | China | A | |
| CN1482932A | China | A | |
| CN1482933A | China | A | |
| KR20040023580A | Republic of Korea | A | |
| US2004054318A1 | United States of America | A1 | |
| US2004054319A1 | United States of America | A1 | |
| US2004054328A1 | United States of America | A1 | |
| US2004054329A1 | United States of America | A1 | |
| US2004073173A1 | United States of America | A1 | |
| US2004078001A1 | United States of America | A1 | |
| MXPA03005575A | Mexico | A | |
| MXPA03005576A | Mexico | A | |
| MXPA03005589A | Mexico | A | |
| MXPA03005590A | Mexico | A | |
| MXPA03005591A | Mexico | A |
101 legal events, as 15 offices reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | Office | |
|---|---|---|---|
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Ep patent has lapsedLapsedEUG | EUG | SE | |
| Patent expired after termination of 20 yearsExpiredPE20 | PE20 | GB | |
| Ep patent expiredExpiredEUP | EUP | DK | |
| Patent ceasedCeasedPL | PL | CH | |
| Expiry of rightR071 | R071 | DE | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Name/firm changedPFA | PFA | CH | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Announcement of lapse in spainLapsedFD2A | FD2A | ES | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Ep patent has been republished in amended form after opposition at epoOppositionRPEO | RPEO | SE | |
| Amended ep patent with danish claimsT4 | T4 | DK | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Maintained in amend formAELC | AELC | CH | |
| Patent maintained in amended form27A | 27A | EP | |
| Designated contracting statesAK | AK | EP | |
| Epo decision maintaining patent in amended form now finalR102 | R102 | DE | |
| Patent maintained in amended formORIGINAL CODE: 0009272PUAH | PUAH | EP | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: PATENT MAINTAINED AS AMENDEDSTAA | STAA | EP | |
| Lapsed because of non-payment of the annual feeLapsedMM | MM | BE | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Fee paymentPLFP | PLFP | FR | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Patent lapsedLapsedMM4A | MM4A | IE | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Appeal procedure closedAppealORIGINAL CODE: EPIDOSNNOA9OAPBU | APBU | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapse because of not paying annual feesLapsedMM01 | MM01 | AT | |
| Lapsed because of non-payment of the annual feeLapsedMM | MM | NL | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Party data changed (patent owner data changed or rights of a patent transferred)RAP2 | RAP2 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Transmission of propertyTP | TP | FR | |
| Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)REGISTERED BETWEEN 20170105 AND 20170111732E | 732E | GB | |
| Change of applicant/patenteeR081 | R081 | DE | |
| Change of representativeR082 | R082 | DE | |
| Fee paymentPLFP | PLFP | FR | |
| New agentNV | NV | CH | |
| AssignmentPUE | PUE | CH | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Opposition filed (corrected)OppositionR26 | R26 | EP | |
| Opposition data, opponent's data or that of the opponent's representative modifiedOppositionORIGINAL CODE: 0009299OPPOPLAB | PLAB | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Fee paymentPLFP | PLFP | FR | |
| Receipt of observations in appeal recordedAppealORIGINAL CODE: EPIDOSNOBA4OAPCA | APCA | EP | |
| Invitation to file observations in appeal sentAppealORIGINAL CODE: EPIDOSNOBA2OAPBY | APBY | EP | |
| Date of receipt of statement of grounds of appeal recordedAppealORIGINAL CODE: EPIDOSNNOA3OAPBQ | APBQ | EP | |
| Appeal reference recordedAppealORIGINAL CODE: EPIDOSNREFNOAPBM | APBM | EP | |
| Date of receipt of notice of appeal recordedAppealORIGINAL CODE: EPIDOSNNOA2OAPBP | APBP | EP | |
| Appeal reference modifiedAppealORIGINAL CODE: EPIDOSCREFNOAPAH | APAH | EP | |
| Appeal reference recordedAppealORIGINAL CODE: EPIDOSNREFNOAPBM | APBM | EP | |
| Date of receipt of notice of appeal recordedAppealORIGINAL CODE: EPIDOSNNOA2OAPBP | APBP | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Reply of patent proprietor to notice(s) of opposition receivedOppositionORIGINAL CODE: EPIDOSNOBS3PLBB | PLBB | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Information modified related to communication of a notice of opposition and request to file observations + time limitOppositionORIGINAL CODE: EPIDOSCOBS2PLAF | PLAF | EP | |
| Nl: opposition has been filed with the epoOppositionNLR1 | NLR1 | EP | |
| Notice of opposition and request to file observation + time limit sentOppositionORIGINAL CODE: EPIDOSNOBS2PLAX | PLAX | EP | |
| Opposition filedOpposition26 | 26 | EP | |
| Opposition filedOppositionORIGINAL CODE: 0009260PLBI | PLBI | EP | |
| Definitive protectionFG2A | FG2A | ES | |
| Fr: translation filedET | ET | EP | |
| Standard patents granted in hong kongGrantedGR | GR | HK | |
| Ep patent with danish claimsT3 | T3 | DK | |
| Ep patent validated in greeceEP | EP | GR | |
| Translation of granted ep patentGrantedTRGR | TRGR | SE | |
| Translation is availableAVAILABILITY OF NATIONAL TRANSLATIONSC4A | SC4A | PT | |
| European patents granted designating irelandGrantedFG4D | FG4D | IE | |
| Corresponds to:REF | REF | EP | |
| European patent takes effect as a national patent in ch/liEP | EP | CH | |
| Designated contracting statesAK | AK | EP | |
| European patent grantedGrantedFG4D | FG4D | GB | |
| (expected) grantORIGINAL CODE: 0009210GRAA | GRAA | EP | |
| Grant fee paidORIGINAL CODE: EPIDOSNIGR3GRAS | GRAS | EP | |
| Despatch of communication of intention to grant a patentORIGINAL CODE: EPIDOSNIGR1GRAP | GRAP | EP | |
| Requests to designate patent in hong kongDE | DE | HK | |
| First examination report despatched17Q | 17Q | EP | |
| Request for examination filed17P | 17P | EP | |
| Designated contracting statesAK | AK | EP | |
| Request for extension of the european patentAX | AX | EP |
Numbers
- Publication
- 1349593
- Publication, DOCDB
- 1349593
- Publication, EPODOC
- EP1349593
- Application
- 12720975
- Application, DOCDB
- 01272097
- Application, EPODOC
- EP20010272097
Titles3
- German
- SCHREIBSTIFTARTIGER INJEKTOR MIT EINER ELEKTRONISCHEN STEUEREINHEIT
- English
- PEN-TYPE INJECTOR HAVING AN ELECTRONIC CONTROL UNIT
- French
- INJECTEUR AU FORMAT STYLO AVEC UNITE DE COMMANDE ELECTRONIQUE
Classification
- CPC, 13
- A61M5/14244
- A61M5/24
- A61M5/14566
- A61M5/20
- A61M5/31525
- A61M5/31546
- A61M2005/31588
- A61M2205/215
- A61M2205/50
- A61M2205/6018
- A61M2205/8206
- Y10S128/01
- G16H20/17
- IPC, 8
- A61M5 24
- A61M5 315
- A61M5 172
- A61M5 145
- A61M5 142
- A61M1 36
- A61M5 168
- A61M5 20
Designated states20
- Contracting states, 20
- Austria
- Belgium
- Switzerland
- Cyprus
- Germany
- Denmark
- Spain
- Finland
- France
- United Kingdom
- Greece
- Ireland
- Italy
- Liechtenstein
- Luxembourg
- Monaco
- Netherlands (Kingdom of the)
- Portugal
- Sweden
- Türkiye